FEB 13, 2019 09:00 AM PST

Making Data Fly in Formation

C.E. CREDITS: RACE
Speakers
  • CEO & Founder, RockStep Solutions
    Biography
      Chuck Donnelly is CEO and co-founder of RockStep Solutions, a company focused on SaaS informatics solutions for biomedical research. Prior to RockStep, Chuck was the Director of Computational Sciences of the Jackson Laboratory (JAX), a genetics research institute focused on the study of the biology and genetics of human diseases. For the past 25 years, Chuck has led innovative technology development teams both at JAX and UC Berkeley (UCB) with funding from the NIH, HHMI, and NASA. At UC Berkeley, Chuck developed novel signal detection algorithms and real-time flight software for astrophysics telescopes operating on space orbiting platforms. He is currently the principal investigator on a recently awarded innovation grant from the NIH to develop a next generation platform for animal lab informatics. He has lectured around the world and published articles on algorithms and research information systems. RockStep Solutions recently released an informatics platform for drug discovery called Climb™. Climb is a SaaS collaboration suite for managing preclinical research operations and data. RockStep is revolutionizing research laboratory workflows with state-of-the-art Azure-cloud technologies such as IoT and Machine Learning.
    • Vice President/Principal, RockStep Solutions
      Biography
        Julie Morrison is Vice President and a Principal of RockStep Solutions, a SaaS informatics company with solutions for data and operations management in drug discovery research. Julie manages RockStep's product and sales teams and works closely with the CEO and Scientific Advisory Board in developing company strategy. Julie began her technical career at The Jet Propulsion Laboratory in Pasadena, California, where she worked on developing a biosensor to detect Bacillus spores in space. She also worked at IDEXX Laboratories, where she developed novel assays for testing public drinking water supplies. Prior to joining RockStep, Julie founded several science based small businesses. Julie has lectured on information management in animal model research and published thought-leadership articles on data and operations management systems for the lab of the future. Julie has a degree in Microbiology from the University of Maine.

      Abstract:

      In biomedical research, data should be treated as first-class corporate assets--they were expensive to create, they are expensive to maintain, and they have future business value. The petabytes of data generated for one NME could have high impact when combined with other data across therapeutic areas, informing new discoveries and accelerating new drugs to market. However, data are often stored in share folders where they are siloed and lie fallow because they are nearly impossible to find and reuse. Fractured data environments inhibit analytical strategies, decrease security, and ultimately place a drag on ROI. Like fighter jets flying in formation, the power and value of scientific data is enhanced when data “fly in formation.” In this presentation, the authors challenge the status quo and ask the audience to imagine a future where precision informatics tools are deployed to manage laboratory operations and integrate legacy data with incoming data across global sites and therapeutic areas. They will discuss how the cloud and the edge, with IoT, artificial intelligence, and machine learning, are transforming research, enabling science, accelerating discovery, and improving ROI. 

      Learning Objectives: 

      1. What do we mean by, Data 360o and Situational Awareness? Why are these concepts so important to science and ROI?  With these concepts in mind, the attendees will learn about considerations and common pitfalls to avoid when evaluating informatics technologies.
      2. Why is data aggregation and data harmonization so important and what technology tools can help implement these related concepts? As we consider data aggregation, what is a things-platform, and how will these platforms be integral components in the future lab.
      3. Peering into the future, the authors will discuss emergent technologies and how they will be soon be transforming research workflows.


      Show Resources
      You May Also Like
      SEP 05, 2019 04:00 PM CEST
      C.E. CREDITS
      SEP 05, 2019 04:00 PM CEST
      DATE: September 5, 2019TIME: 7:00am PT, 10:00am ET, 4:00pm CEST PCR (Polymerase Chain Reaction) has gone through a massive evolution since its development in 1983. Besides it...
      OCT 02, 2019 11:00 AM PDT
      OCT 02, 2019 11:00 AM PDT
      DATE: October 2, 2019TIME: 11:00am PDT, 2:00pm EDT Ditch the Excel spreadsheets and manage your molecular workflows entirely in your LIMS Achieve configuration of molecular workf...
      JUN 05, 2019 05:00 PM CEST
      C.E. CREDITS
      JUN 05, 2019 05:00 PM CEST
      DATE: June 5, 2019TIME: 8:00am PDT, 11:00am EDT, 5:00pm CEST Eukaryotic cell cultures respond to the most subtle influence. Apart from the risk of contamination, minimal chan...
      MAY 16, 2019 04:00 PM CEST
      C.E. CREDITS
      MAY 16, 2019 04:00 PM CEST
      DATE: May 16, 2019TIME: 7:00am PDT, 10:00am EDT, 4:00pm CEST The emergence of NGS is revolutionizing the microbiological sciences and transforming medicine. Deep sequencing has...
      NOV 18, 2019 07:00 AM PST
      Add to Calendar Select one of the following: iCal Google Calendar Outlook Calendar Yahoo Calendar
      C.E. CREDITS
      NOV 18, 2019 07:00 AM PST
      Add to Calendar Select one of the following: iCal Google Calendar Outlook Calendar Yahoo Calendar
      DATE: November 18, 2019TIME: 7:00am PST, 11:00am EST, 4:00pm CEWT How often do you pipette in your cell culture lab every day? Usually, we do it so often that we tend stop th...
      AUG 27, 2019 09:00 AM PDT
      C.E. CREDITS
      AUG 27, 2019 09:00 AM PDT
      DATE: August 27, 2019 TIME: 9:00am PDT, 12:00pm EDT Immunotherapies targeting PD-1 or PD-L1 have proven remarkably effective for treating cancer in some patients, with considerabl...
      Loading Comments...
      Show Resources